NURIX THERAPEUTICS INC (NRIX) Stock Price, Quote, News and Overview
NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD
NRIX Quote, Performance and Key Statistics
16.87
-0.17 (-1%)
The current stock price of NRIX is 16.87 USD. In the past month the price decreased by -15.48%. In the past year, price increased by 65.39%.
NRIX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NRIX
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 284 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. The company DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Company Info
NURIX THERAPEUTICS INC
1700 Owens St Ste 205
San Francisco CALIFORNIA 94158 US
CEO: Arthur T. Sands
Employees: 284
Company Website: https://www.nurixtx.com/
Investor Relations: https://ir.nurixtx.com/
Phone: 14156605320
NURIX THERAPEUTICS INC / NRIX FAQ
What is the stock price of NURIX THERAPEUTICS INC today?
The current stock price of NRIX is 16.87 USD. The price decreased by -1% in the last trading session.
What is the ticker symbol for NURIX THERAPEUTICS INC stock?
The exchange symbol of NURIX THERAPEUTICS INC is NRIX and it is listed on the Nasdaq exchange.
On which exchange is NRIX stock listed?
NRIX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NURIX THERAPEUTICS INC stock?
24 analysts have analysed NRIX and the average price target is 32.75 USD. This implies a price increase of 94.15% is expected in the next year compared to the current price of 16.87. Check the NURIX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NURIX THERAPEUTICS INC worth?
NURIX THERAPEUTICS INC (NRIX) has a market capitalization of 1.28B USD. This makes NRIX a Small Cap stock.
How many employees does NURIX THERAPEUTICS INC have?
NURIX THERAPEUTICS INC (NRIX) currently has 284 employees.
What are the support and resistance levels for NURIX THERAPEUTICS INC (NRIX) stock?
NURIX THERAPEUTICS INC (NRIX) has a support level at 16.86 and a resistance level at 17.45. Check the full technical report for a detailed analysis of NRIX support and resistance levels.
Is NURIX THERAPEUTICS INC (NRIX) expected to grow?
The Revenue of NURIX THERAPEUTICS INC (NRIX) is expected to grow by 1.15% in the next year. Check the estimates tab for more information on the NRIX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NURIX THERAPEUTICS INC (NRIX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NRIX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NRIX, evaluating the profitability, health, valuation and growth aspects
- NURIX THERAPEUTICS INC (NRIX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NURIX THERAPEUTICS INC (NRIX) Sales and EPS estimates to see what analysts future expectations are.
- NURIX THERAPEUTICS INC (NRIX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NURIX THERAPEUTICS INC (NRIX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NURIX THERAPEUTICS INC (NRIX) Stock Chart to make your own analysis
- NURIX THERAPEUTICS INC (NRIX) Latest news and press-releases to stay up to date.
Does NURIX THERAPEUTICS INC (NRIX) stock pay dividends?
NRIX does not pay a dividend.
When does NURIX THERAPEUTICS INC (NRIX) report earnings?
NURIX THERAPEUTICS INC (NRIX) will report earnings on 2025-04-08, before the market open.
What is the Price/Earnings (PE) ratio of NURIX THERAPEUTICS INC (NRIX)?
NURIX THERAPEUTICS INC (NRIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.89).
What is the Short Interest ratio of NURIX THERAPEUTICS INC (NRIX) stock?
The outstanding short interest for NURIX THERAPEUTICS INC (NRIX) is 14.7% of its float. Check the ownership tab for more information on the NRIX short interest.
NRIX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NRIX. When comparing the yearly performance of all stocks, NRIX is one of the better performing stocks in the market, outperforming 86.38% of all stocks.
NRIX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NRIX. While NRIX has a great health rating, there are worries on its profitability.
NRIX Financial Highlights
Over the last trailing twelve months NRIX reported a non-GAAP Earnings per Share(EPS) of -2.89. The EPS decreased by -9.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.92% | ||
| ROE | -36.73% | ||
| Debt/Equity | 0 |
NRIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NRIX. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -9.65% and a revenue growth 1.15% for NRIX